Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia

被引：1
|
作者：
Petersdorf, Stephen [2 ]
Kopecky, Kenneth [1 ]
Stuart, Robert K. [3 ]
Larson, Richard A. [4 ]
Nevill, Thomas J. [5 ]
Stenke, Leif [6 ]
Slovak, Marilyn L. [7 ]
Tallman, Martin S. [8 ]
Willman, Cheryl L. [9 ]
Erba, Harry [10 ]
Appelbaum, Frederick R. [11 ]
机构：
[1] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Med Univ S Carolina, Charleston, SC 29425 USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Univ British Columbia, Div Hematol & Leukemia, BMt, Vancouver, BC V5Z 1M9, Canada
[6] Karolinska Univ Hosp, Stockholm, Sweden
[7] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[8] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[9] Univ New Mexico, Canc Res & Treatment Ctr, Canc Res Facil, Albuquerque, NM 87131 USA
[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[11] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：326 / 327
页数：2
相关论文
共 10 条
  • [1] Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
    Walter, Roland B.
    Medeiros, Bruno C.
    Powell, Bayard L.
    Schiffer, Charles A.
    Appelbaum, Frederick R.
    Estey, Elihu H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (05): : 739 - 742
  • [2] PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)
    Walter, B.
    Medeiros, B.
    Nielsen-Stoeck, M.
    Harrington, E.
    Powell, B.
    Schiffer, C.
    Appelbaum, F.
    Estey, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 29 - 30
  • [3] Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia
    Brunnberg, Uta
    Mohr, Michael
    Noppeney, Richard
    Duerk, Heinz A.
    Sauerland, Maria Cristina
    Mueller-Tidow, Carsten
    Krug, Utz O.
    Koschmieder, Steffen
    Kessler, Torsten
    Mesters, Rolf M.
    Schulz, Christiane
    Buchner, Thomas
    Ehninger, Gerhard
    Duehrsen, Ulrich
    Serve, Hubert
    Berdel, Wolfgang E.
    BLOOD, 2010, 116 (21) : 152 - 152
  • [4] Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500)
    Petersdorf, Stephen H.
    Rankin, Cathryn
    Head, David R.
    Terebelo, Howard R.
    Willman, Cheryl L.
    Balcerzak, Stanley P.
    Karnad, Arland B.
    Dakhil, Shaker R.
    Appelbaum, Frederick R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (12) : 1056 - 1062
  • [5] A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients
    Nand, Sucha
    Othus, Megan
    Godwin, John E.
    Willman, Cheryl L.
    Norwood, Thomas
    Erba, Harry Paul
    Howard, Dianna
    Coutre, Steven E.
    Appelbaum, Frederick R.
    BLOOD, 2012, 120 (21)
  • [6] A randomized, phase III trial of mitoxantrone (M) plus etoposide (E) versus daunomycin (D) plus cytarabine (A) as induction therapy in patients over age 55 with previously untreated acute myeloid leukemia (AML): Southwest oncology group study 9333.
    Anderson, JE
    Kopecky, KJ
    Head, D
    O'Donnell, MR
    Luthardt, FW
    Norwood, TH
    Willman, CL
    Balcerzak, SP
    Johnson, DB
    Appelbaum, FR
    BLOOD, 1999, 94 (10) : 383A - 383A
  • [7] A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol-Report on the good-risk patients
    Nand, Sucha
    Gundacker, Holly
    Godwin, John E.
    Willman, Cheryl L.
    Norwood, Thomas
    Erba, Harry Paul
    Howard, Dianna S.
    Coutre, Steven E.
    Othus, Megan
    Appelbaum, Frederick R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial
    van Dijk, Anneke D.
    Ruvolo, Peter P.
    Hoff, Fieke W.
    Qiu, Yihua
    Gamis, Alan S.
    Aplenc, Richard
    Kolb, Anders E.
    Alonzo, Todd A.
    Gerbing, Robert B.
    de Bont, Eveline S.
    Bruggeman, Sophia W. M.
    Horton, Terzah M.
    Kornblau, Steven M.
    BLOOD, 2019, 134
  • [9] Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502
    Attar, Eyal C.
    Donohue, Kathleen A.
    Amrein, Philip C.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Kolitz, Jonathan E.
    Powell, Bayard L.
    Voorhees, Peter M.
    Wang, Eunice S.
    Blum, William
    Booth, Allison
    Stone, Richard M.
    Moser, Barry K.
    Larson, Richard
    BLOOD, 2010, 116 (21) : 150 - 150
  • [10] SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
    Garcia-Manero, Guillermo
    Othus, Megan
    Pagel, John M.
    Radich, Jerald P.
    Fang, Min
    Rizzieri, David A.
    Marcucci, Guido
    Strickland, Stephen A.
    Litzow, Mark
    Savoie, Mary Lynn
    Medeiros, Bruno C.
    Sekeres, Mikkael A.
    Lin, Tara L.
    Uy, Geoffrey L.
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Larson, Richard A.
    Stone, Richard M.
    Claxton, David F.
    Essell, James
    Luger, Selina
    Mohan, Sanjay R.
    Moseley, Anna
    Appelbaum, Frederick R.
    Erba, Harry P.
    BLOOD, 2016, 128 (22)
1